# Evidence search
(under construction)
## Inclusion criteria
Randomized trials of amy cancer that compare pembrolizumab to placebo or another active treatment.

## Reconciliation tables
(under construction)
* [Comparison of included studies with prior systematic reviews](../reconciliation-tables)

## PubMed
### Boolean term searching
(under construction)
[pembrolizumab AND random\*](https://www.ncbi.nlm.nih.gov/pubmed?cmd=Search&term=pembrolizumab%20AND%20random*)
* Retrieves X articles in hand (100% sensitivity) (search 6/19/2017)
* X total citations found (search results reviewed 6/x/2017; 0 additional studies found)

### Vector searching ('Related citations' search)
(under construction)
Seed articles: PMIDs [26314489,28552271,28140013,9851958,2897005](https://www.ncbi.nlm.nih.gov/pubmed?cmd=Search&tool=SUMSearch2plugins&otool=kumclib&term=26314489%2028552271%2028140013%209851958%202897005)
* [X citations](https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=26314489,28552271,28140013,9851958,2897005)
* NA citations when above limited to years 2014 - 2017 (time period after Cochrane review)
  * [X additional articles found](https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=15570651)

## ClinicalTrials.gov

`pembrolizumab and cancer`
* [889 citations](https://clinicaltrials.gov/ct2/results?term=pembrolizumab&type=Intr&cond=cancer) (search 6/19/2017)
  * Included: pending

## Cochrane Central Register of Controlled Trials (CENTRAL)

`pembrolizumab`
* [665 citations](https://www.cochranelibrary.com/en/search?searchBy=1&searchText=pembrolizumab&isWordVariations=&resultPerPage=25&searchType=basic&forceTypeSelection=true&selectedType=central&displayText=&p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1) (search 12/13/2018)
  * Included: pending

## Cited reference searching
(under construction)

### Identifying seminal studies that are the most highly cited
Reck M, et al; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. PMID: [27718847](http://pubmed.gov/27718847).
 * [2014 citations](https://scholar.google.com/scholar?cites=12334319948115620665&as_sdt=2005&sciodt=0,5&hl=en) (search12/13/2018)

### Searching 'random*' within the highly citing studyies using Google Scholar (4/21/2017)
Mehta et al. 
* [1230 citations](https://scholar.google.com/scholar?hl=en&as_sdt=2005&sciodt=0%2C5&cites=12334319948115620665&scipsc=1&q=randomized&btnG=) (limited to citing articles containing random\*)
* [x additional studies found](https://pubmed.gov/25503625,27045252)

## Other websites:

### ASCO
https://meetinglibrary.asco.org/results/Keywords:%22pembrolizumab%22%20AND%20Keywords:%22randomized%22%20AMD%20%28Keywords:%22HR%22%20OR%20Keywords:%22hazard%22%29

#### Merck
https://www.merck.com/clinical-trials/infographics/oncology.html
